NCT04255979View on ClinicalTrials.gov

A Study of HY209 in Healthy Male Volunteers for Sepsis

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

June 12, 2020

Study Completion Date

June 12, 2020

Conditions
Sepsis
Interventions
DRUG

HY209

6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Shaperon
All Listed Sponsors
lead

Shaperon

INDUSTRY

NCT04255979 - A Study of HY209 in Healthy Male Volunteers for Sepsis | Biotech Hunter | Biotech Hunter